Source: Gilead Sciences.Gilead Sciences surprised investors when it recently announced that it will begin returning some of its cash stockpile to investors in the form of a dividend. Since dividend-paying biotech stocks are a bit of a rarity, we asked two Motley Fool healthcare experts for their opinion on whether Gilead Sciences’ dividend plan makes sense. Read on to learn […]
Hepatitis C treatment has progressed by leaps and bounds in the past few years, and appears to be accelerating even more quickly now. Cure rates have increased, treatment times are plummeting, and side effects are falling away. Is now the time to jump into the biotechs researching new drugs?Industry Focus takes a look at Regulus Therapeutics and Achillion Pharmaceuticals […]
Not many investment pros managed to dump their oil stocks before the price of crude started plummeting last year, but prescient investors who did obviously escaped heavy losses. The big question: Where did they invest the proceeds for greater future gains?One top-ranked money manager, Graham Tanaka, president and senior analyst and portfolio manager at TANAKA Growth Fund (TGFRX), was one […]
OK, listen up – it’s time to “buy the dip.”I’m talking about the biotech dip that just happened. Here’s the deal:A leading biotech company just issued some news that spooked some jittery investors. The stock took a dive, taking the entire sector down a peg or two.But this is just a temporary blip, and it’s handing you a golden chance […]
OK, listen up – it’s time to “buy the dip.”I’m talking about the biotech dip that just happened. Here’s the deal:A leading biotech company just issued some news that spooked some jittery investors. The stock took a dive, taking the entire sector down a peg or two.But this is just a temporary blip, and it’s handing you a golden chance […]
VIDEO UPDATE: Market analysis looking at long term charts, movers on the day, and analysis of 50 stocks with setups and buy points.It was another good day for the indexes and oil as they moved in concert. The S&P 500 gained 1.44% and the NASDAQ 1.09%. Factory orders for December posted a greater-than-expected decline of 3.4%. Analysts expected a decline […]
VIDEO UPDATE: 30m session looking at the long term market charts, top 5 movers on the day, some education, and a kickoff with a personal story of how a stop loss order I had on AMZN bit me for $2,000+, ouch.Indexes finished off a volatile session with strong gains in the closing hour as the S&P 500 closed up 1.30% […]
It’s been shown that dividend-paying stocks outperform their non-dividend paying counterparts, but focusing on dividends may not be the best strategy when it comes to big biotech stocks. Read on to learn why three Motley Fool contributors don’t think it makes sense for these big biotech companies to pay investors a dividend.Cheryl Swanson : Take a little trip through history […]
Source: StockMonkeys.com via Flickr.It’s been a truly transformative year for Gilead Sciences and its shareholders. Even taking into consideration the latest swoon in Gilead’s share price tied to the approval of AbbVie ‘s Viekira Pak and its subsequent multi-year agreement with Express Scripts , Gilead shares are up 25% for the year, essentially doubling the return of the S&P 500 […]
Biotechnology’s mind-numbing share price volatility means that only the most risk-tolerant investors should consider owning them — but for investors with a penchant for risk and a stomach tough enough to handle the inevitable pops and drops, there may be opportunities to discover emerging biotech companies with promising pipelines that could send their shares significantly higher in 2015. Ophthotech Corporation […]
